跳至主要内容
临床试验/NCT01941277
NCT01941277终止不适用

Effect of Exercise on Insulin Resistance

Alere San Diego4 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2014年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
3
试验地点
4
主要终点
A decrease in Insulin Resistance (IR) as measured by a change in IR.

研究概览

简要总结

The purpose of this study is to evaluate the effect of exercise on Insulin Resistance (IR) in subjects who do not routinely exercise and who are at risk of developing diabetes (prediabetes).

It is estimated that approximately 30-90 people will participate in this study at three study sites in the United States and United Kingdom.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 18 to 75 years.
  • Meets one of the three diagnostic criteria listed below (based on screening results or recorded result within one week of enrollment);
  • Fasting plasma or whole blood glucose (fasting defined as no caloric intake for at least 8 hours): 100 ≤ 125 mg/dL (6.0-6.9 mmol/L)
  • HbA1c of 5.7% - 6.4% (39 - 46 mmol/mol)
  • 2-hour plasma glucose of 140-199 mg/dL (7.8-11.0 mmol/L) during an OGTT (as described by the WHO using a glucose load of 75 g anhydrous glucose dissolved in water)
  • No clinically significant adverse exercise response during the maximal graded exercise test

排除标准

  • Weight loss diet program or weight change (>10%) within the past 6 months
  • Daily physical activity of >10,000 steps per day (as measured during the interval between visits 1 and 2)
  • Participates in deliberate structured exercise
  • Pregnant or intending to become pregnant
  • Cognitive or intellectual disability that prevents subject from providing informed consent or following protocol instructions.
  • Unwillingness to participate in all study procedures
  • Inability to give blood through multiple venous phlebotomies or to have an intravenous catheter
  • BMI greater than 40 kg/m2
  • Concurrent participation in another lifestyle modification trial
  • Diagnosis of diabetes based on any one of the following criteria:
  • Fasting plasma or whole blood glucose ≥ 126 mg/dL (7 mmol/L)
  • HbA1c of >6.5% (>47 mmol/mol)
  • 2-hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during an OGTT
  • Any pre-existing or newly discovered medical condition that is deemed likely to put the subject at risk of injury during this trial. This may include but is not limited to:
  • Clinically relevant vascular or cerebrovascular event (e.g. stroke, recurrent transient ischemic attack (TIA), deep venous thrombosis or intracardiac thrombi, clinically significant edema within the previous 6 months
  • Current use of anti-psychotic, anti-convulsant, anti-coagulant, sedative medication, or cognition-enhancing medications
  • Current use of beta blockers (beta-adrenergic blocking agents)
  • Current or previous use (within the past year) of the following medications: diabetes related medications or insulin; metformin; growth hormone; glucagon; dipeptidyl peptidase-4(DPP-4) inhibitors (saxagliptin, stigagliptin); glucagon-Like Peptide-1(GLP-1) mimetics (exenatide, liraglutide); sulfonylurea medication or other potential confounding medications
  • Medical conditon which predetermines insulin resistance (e.g. Marfan syndrome / severe Polycystic ovary syndrome (PCOS) / Cushing syndrome etc.).
  • Fasting triglycerides > 1000 mg/dL.

结局指标

主要结局

A decrease in Insulin Resistance (IR) as measured by a change in IR.

时间窗: change between baseline and 6 weeks

次要结局

未报告次要终点

研究者

发起方
Alere San Diego
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验